拉米夫定联合干扰素治疗干扰素抗病毒失败的慢性乙型肝炎疗效分析  

Clinical Study of Lamivudine Combined with Interferon in Chronic HBV Infection After Failure of Interferon Treatment

作　　者：那琳琳[1] 王莹[1] 

机构地区：[1]哈尔滨二四二医院,黑龙江哈尔滨150060

出　　处：《哈尔滨医药》2011年第5期326-327,共2页Harbin Medical Journal

摘　　要：目的分析单用干扰素抗病毒失败的慢性乙型肝炎改用拉米夫定联合干扰素的疗效。方法选择36例单用干扰素抗病毒失败CHB患者,给予拉米夫定100mg,每日1次,疗程不定,联合干扰素治疗,500万IU,肌肉注射,隔日1次,疗程12个月;观察治疗后12 w、24 w、48 w及停药后第12周、第24周肝功、乙肝病毒标志物及HBV-DNA情况。结果治疗48 w后ALT复常率94.4%,HBeAg阴转率52.7%,HBeAg转换率41.7%,HBV-DNA阴转率94.4%。结论拉米夫定联合干扰素治疗慢性乙型病毒性肝炎疗效显著,值得临床应用。Objective To investigate the clinical treatment efficacy of chronic hepatitis B（CHB） with lamivudine combined with interferon after failure of only interferon treatment. Methods After failure of only interferon treatment,the 36 patients with CHB received lamivudine 100mg/d once every day,combined with 5000000IU/d of interferon,im,qod for 12months.The control group received lamivudine 100mg/d of oral for 12months.The liver function,HBVM and HBV-DNA of all patients were observed at the end of 12,24,48 weeks after the treatment and at the end of 12,24 weeks after treatment. Results ALT normalization occurred 94.4%;the serum conversion rate of HBeAg was 52.7%;the sero-conversion rate of HBeAg was 41.7%;the serum conversion rate of HBV-DNA was 94.4%. Conclusion Treatment for chronic hepatitis B with Lamivudine combined with interferon is very effective,and was well worth clinical popularizing.

关 键 词：拉米夫定 干扰素 联合治疗 慢性乙型肝炎 

分 类 号：R512.6[医药卫生—内科学]